메뉴 건너뛰기




Volumn 35, Issue 1, 2013, Pages 4-27

Rivaroxaban: An Oral Factor Xa Inhibitor

Author keywords

Anticoagulants; Atrial fibrillation thromboembolism prophylaxis; Rivaroxaban; Venous thromboembolism prophylaxis; Venous thromboembolism treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALUMINUM MAGNESIUM HYDROXIDE; ANTIVITAMIN K; CARBAMAZEPINE; DABIGATRAN; ENOXAPARIN; KETOCONAZOLE; NAPROXEN; OMEPRAZOLE; PHENYTOIN; RANITIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; WARFARIN;

EID: 84872395561     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.12.005     Document Type: Review
Times cited : (30)

References (61)
  • 1
    • 84856784474 scopus 로고    scopus 로고
    • Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    • Ageno W.A., Gallus Wittkowsky A.S., et al. Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(Suppl):e44S-e88S.
    • (2012) Chest , vol.141 , Issue.SUPPL
    • Ageno, W.A.1    Gallus Wittkowsky, A.S.2
  • 2
    • 74249107395 scopus 로고    scopus 로고
    • The clinical implications of new oral anticoagulants: Will the potential advantages be achieved?
    • Phillips K.W., Ansell J. The clinical implications of new oral anticoagulants: Will the potential advantages be achieved?. Thromb Haemost 2010, 103:34-39.
    • (2010) Thromb Haemost , vol.103 , pp. 34-39
    • Phillips, K.W.1    Ansell, J.2
  • 3
    • 85045354463 scopus 로고    scopus 로고
    • [package insert], Accessed November 28, 2012
    • Xarelto (rivaroxaban) [package insert], Accessed November 28, 2012. http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100.
    • Xarelto (rivaroxaban)
  • 5
    • 80051564817 scopus 로고    scopus 로고
    • European Medicines Agency, Accessed November 30, 2012
    • Summary of product characteristics for Xarelto European Medicines Agency, Accessed November 30, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf.
    • Summary of product characteristics for Xarelto
  • 6
    • 84872405418 scopus 로고    scopus 로고
    • Health Canada, Accessed November 28, 2012
    • Product Monograph for Xarelto Health Canada, Accessed November 28, 2012. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/sbd_smd_2009_xarelto_119111-eng.pdf.
    • Product Monograph for Xarelto
  • 8
    • 84872368683 scopus 로고    scopus 로고
    • European Medicines Agency, Committee for Medicinal Products for Human Use, Accessed November 28, 2012
    • Summary of Opinion European Medicines Agency, Committee for Medicinal Products for Human Use, Accessed November 28, 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000944/smops/Positive/human_smop_000441.jsp%26mid=WC0b01ac058001d127.
    • Summary of Opinion
  • 9
    • 34147147085 scopus 로고    scopus 로고
    • In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban
    • Gerotziafas G.T., Elalamy I., Depasse F., et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007, 5:886-888.
    • (2007) J Thromb Haemost , vol.5 , pp. 886-888
    • Gerotziafas, G.T.1    Elalamy, I.2    Depasse, F.3
  • 10
    • 78349241402 scopus 로고    scopus 로고
    • The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation
    • Green L., Lawrie A.S., Patel S., et al. The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. Br J Haematol 2010, 15:469-476.
    • (2010) Br J Haematol , vol.15 , pp. 469-476
    • Green, L.1    Lawrie, A.S.2    Patel, S.3
  • 11
    • 66449099711 scopus 로고    scopus 로고
    • Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans
    • Weinz C., Schwarz T., Kubitza D., et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009, 37:1056-1064.
    • (2009) Drug Metab Dispos , vol.37 , pp. 1056-1064
    • Weinz, C.1    Schwarz, T.2    Kubitza, D.3
  • 12
    • 25844525489 scopus 로고    scopus 로고
    • Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
    • Kubitza D., Becka M., Voith B., et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005, 78:412-421.
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 412-421
    • Kubitza, D.1    Becka, M.2    Voith, B.3
  • 13
    • 29144518504 scopus 로고    scopus 로고
    • Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects
    • Kubitza D., Becka M., Wensing G., et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005, 61:873-880.
    • (2005) Eur J Clin Pharmacol , vol.61 , pp. 873-880
    • Kubitza, D.1    Becka, M.2    Wensing, G.3
  • 14
    • 34250166525 scopus 로고    scopus 로고
    • Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in healthy subjects
    • Mueck W., Becka M., Kubitza D., et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther 2007, 45:335-344.
    • (2007) Int J Clin Pharmacol Ther , vol.45 , pp. 335-344
    • Mueck, W.1    Becka, M.2    Kubitza, D.3
  • 15
    • 67650932119 scopus 로고    scopus 로고
    • Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese patients
    • Zhao X., Sun P., Zhou Y., et al. Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese patients. Br J Clin Pharmacol 2009, 68:77-88.
    • (2009) Br J Clin Pharmacol , vol.68 , pp. 77-88
    • Zhao, X.1    Sun, P.2    Zhou, Y.3
  • 16
    • 80052485992 scopus 로고    scopus 로고
    • Rivaroxaban population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention
    • Mueck W., Lensing A.W.A., Agnelli G., et al. Rivaroxaban population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011, 50:675-686.
    • (2011) Clin Pharmacokinet , vol.50 , pp. 675-686
    • Mueck, W.1    Lensing, A.W.A.2    Agnelli, G.3
  • 17
    • 55549139511 scopus 로고    scopus 로고
    • Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in health elderly subjects
    • Kubitza D., Becka M., Roth A., et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in health elderly subjects. Curr Med Res Opin 2008, 24:2757-2765.
    • (2008) Curr Med Res Opin , vol.24 , pp. 2757-2765
    • Kubitza, D.1    Becka, M.2    Roth, A.3
  • 18
    • 74249121331 scopus 로고    scopus 로고
    • Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban-an oral, direct factor Xa inhibitor-in elderly Chinese subjects
    • Jiang J., Hu Y., Zhang J., et al. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban-an oral, direct factor Xa inhibitor-in elderly Chinese subjects. Thromb Haemost 2010, 103:234-241.
    • (2010) Thromb Haemost , vol.103 , pp. 234-241
    • Jiang, J.1    Hu, Y.2    Zhang, J.3
  • 19
    • 33846448135 scopus 로고    scopus 로고
    • Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
    • Kubitza D., Becka M., Zuehlsdorf M., et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007, 47:218-226.
    • (2007) J Clin Pharmacol , vol.47 , pp. 218-226
    • Kubitza, D.1    Becka, M.2    Zuehlsdorf, M.3
  • 20
    • 42949123582 scopus 로고    scopus 로고
    • Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery
    • Mueck W., Eriksson B.I., Bauer K.A., et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008, 47:203-216.
    • (2008) Clin Pharmacokinet , vol.47 , pp. 203-216
    • Mueck, W.1    Eriksson, B.I.2    Bauer, K.A.3
  • 21
    • 51349095537 scopus 로고    scopus 로고
    • Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
    • Mueck W., Borris L.C., Dahl O.E., et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008, 100:453-461.
    • (2008) Thromb Haemost , vol.100 , pp. 453-461
    • Mueck, W.1    Borris, L.C.2    Dahl, O.E.3
  • 22
    • 84862133430 scopus 로고    scopus 로고
    • Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes
    • Xu X.S., Moore K., Burton P., et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br J Clin Pharmacol 2012, 74:86-97.
    • (2012) Br J Clin Pharmacol , vol.74 , pp. 86-97
    • Xu, X.S.1    Moore, K.2    Burton, P.3
  • 23
    • 78649289929 scopus 로고    scopus 로고
    • Effect of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
    • Kubitza D., Becka M., Mueck W., et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010, 70:703-712.
    • (2010) Br J Clin Pharmacol , vol.70 , pp. 703-712
    • Kubitza, D.1    Becka, M.2    Mueck, W.3
  • 24
    • 33747068794 scopus 로고    scopus 로고
    • Safety, tolerability, pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-affected by aspirin
    • Kubitza D., Becka M., Mueck W., et al. Safety, tolerability, pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-affected by aspirin. J Clin Pharmacol 2006, 46:981-990.
    • (2006) J Clin Pharmacol , vol.46 , pp. 981-990
    • Kubitza, D.1    Becka, M.2    Mueck, W.3
  • 25
    • 33947205635 scopus 로고    scopus 로고
    • Rivaroxaban (BAY 59-7939)-an oral, direct factor Xa inhibitor-has no clinically relevant interaction with naproxen
    • Kubitza D., Becka M., Mueck W., et al. Rivaroxaban (BAY 59-7939)-an oral, direct factor Xa inhibitor-has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007, 63:469-476.
    • (2007) Br J Clin Pharmacol , vol.63 , pp. 469-476
    • Kubitza, D.1    Becka, M.2    Mueck, W.3
  • 26
    • 33645779998 scopus 로고    scopus 로고
    • Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral direct factor Xa inhibitor, in healthy subjects
    • Kubitza D., Becka M., Zuehlsdorf M., et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006, 46:549-558.
    • (2006) J Clin Pharmacol , vol.46 , pp. 549-558
    • Kubitza, D.1    Becka, M.2    Zuehlsdorf, M.3
  • 27
    • 83155181625 scopus 로고    scopus 로고
    • Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban
    • Moore K.T., Plotnikov A.N., Thyssen A., et al. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J Cardiovasc Pharmacol 2011, 58:581-588.
    • (2011) J Cardiovasc Pharmacol , vol.58 , pp. 581-588
    • Moore, K.T.1    Plotnikov, A.N.2    Thyssen, A.3
  • 28
    • 80053571188 scopus 로고    scopus 로고
    • Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects
    • Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
    • (2011) Circulation , vol.124 , pp. 1573-1579
    • Eerenberg, E.S.1    Kamphuisen, P.W.2    Sijpkens, M.K.3
  • 29
    • 84864370719 scopus 로고    scopus 로고
    • Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban
    • Marlu R., Hodaj Enkelejda, Paris A., et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. Thromb Haemost 2012, 108:217-224.
    • (2012) Thromb Haemost , vol.108 , pp. 217-224
    • Marlu, R.1    Hodaj, E.2    Paris, A.3
  • 30
    • 45949099359 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
    • Eriksson B.I., Borris L.C., Friedman R.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358:2765-2775.
    • (2008) N Engl J Med , vol.358 , pp. 2765-2775
    • Eriksson, B.I.1    Borris, L.C.2    Friedman, R.J.3
  • 31
    • 46049106502 scopus 로고    scopus 로고
    • Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial
    • Kakkar A.K., Brenner B., Dahl O.E., et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet 2008, 372:31-39.
    • (2008) Lancet , vol.372 , pp. 31-39
    • Kakkar, A.K.1    Brenner, B.2    Dahl, O.E.3
  • 32
    • 45949103416 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
    • Lassen M.R., Ageno W., Borris L.C., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358:2776-2786.
    • (2008) N Engl J Med , vol.358 , pp. 2776-2786
    • Lassen, M.R.1    Ageno, W.2    Borris, L.C.3
  • 33
    • 65549169515 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomised trial
    • Turpie A.G.G., Lassen M.R., Davidson B.L., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomised trial. Lancet 2009, 1673-1680.
    • (2009) Lancet , pp. 1673-1680
    • Turpie, A.G.G.1    Lassen, M.R.2    Davidson, B.L.3
  • 34
    • 80052341686 scopus 로고    scopus 로고
    • Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
    • Cohen AT, Spiro TE, BÛller J, et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thombolysis 201;31:407-416.
    • J Thromb Thombolysis , vol.201 , Issue.31 , pp. 407-416
    • Cohen, A.T.1    Spiro, T.E.2    Buller, J.3
  • 36
    • 78650619315 scopus 로고    scopus 로고
    • Oral rivaroxaban for symptomatic venous thromboembolism
    • EINSTEIN investigators
    • Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510. EINSTEIN investigators.
    • (2010) N Engl J Med , vol.363 , pp. 2499-2510
  • 37
    • 84859385808 scopus 로고    scopus 로고
    • Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
    • EINSTEIN-PE investigators
    • Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287-1297. EINSTEIN-PE investigators.
    • (2012) N Engl J Med , vol.366 , pp. 1287-1297
  • 38
    • 84862907587 scopus 로고    scopus 로고
    • Rivaroxaban in patients with a recent acute coronary syndrome
    • Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366:9-19.
    • (2012) N Engl J Med , vol.366 , pp. 9-19
    • Mega, J.L.1    Braunwald, E.2    Wiviott, S.D.3
  • 39
    • 80052592404 scopus 로고    scopus 로고
    • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    • Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
    • (2011) N Engl J Med , vol.365 , pp. 883-891
    • Patel, M.R.1    Mahaffey, K.W.2    Garg, J.3
  • 40
    • 0034612319 scopus 로고    scopus 로고
    • Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial
    • Heit J.A., Elliott C.G., Trowbridge A.A., et al. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Int Med 2000, 132:853-861.
    • (2000) Ann Int Med , vol.132 , pp. 853-861
    • Heit, J.A.1    Elliott, C.G.2    Trowbridge, A.A.3
  • 41
    • 84856797169 scopus 로고    scopus 로고
    • Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    • Falck-Ytter Y., Francis C.W., Johanson N.A., et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(Suppl):e278S-e325S.
    • (2012) Chest , vol.141 , Issue.SUPPL
    • Falck-Ytter, Y.1    Francis, C.W.2    Johanson, N.A.3
  • 42
    • 0031055747 scopus 로고    scopus 로고
    • Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind dose-ranging study
    • Heit J.A., Berkowitz S.D., Bona R., et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind dose-ranging study. Thromb Haemost 1997, 77:32-38.
    • (1997) Thromb Haemost , vol.77 , pp. 32-38
    • Heit, J.A.1    Berkowitz, S.D.2    Bona, R.3
  • 43
    • 65649094404 scopus 로고    scopus 로고
    • Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement
    • Eriksson B.I., Kakkar A.K., Turpie A.G.G., et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009, 91:636-644.
    • (2009) J Bone Joint Surg Br , vol.91 , pp. 636-644
    • Eriksson, B.I.1    Kakkar, A.K.2    Turpie, A.G.G.3
  • 44
    • 78649319886 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials
    • Cao Y.B., Zhang J.D., Shen H., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2010, 66:1099-1108.
    • (2010) Eur J Clin Pharmacol , vol.66 , pp. 1099-1108
    • Cao, Y.B.1    Zhang, J.D.2    Shen, H.3
  • 45
    • 84870880553 scopus 로고    scopus 로고
    • Oral antithrombotic agents for prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association
    • Furie K.L., Goldstein L.B., Albers G.W., et al. Oral antithrombotic agents for prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012, 43:3442-3453.
    • (2012) Stroke , vol.43 , pp. 3442-3453
    • Furie, K.L.1    Goldstein, L.B.2    Albers, G.W.3
  • 46
    • 67649562905 scopus 로고    scopus 로고
    • Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
    • Mega J.L., Braunwald E., Mohanavelu S., et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009, 374:29-38.
    • (2009) Lancet , vol.374 , pp. 29-38
    • Mega, J.L.1    Braunwald, E.2    Mohanavelu, S.3
  • 47
    • 84859603846 scopus 로고    scopus 로고
    • New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Position Paper
    • De Caterina E., Husted S., Wallentin L., et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Position Paper. J Am Coll Cardiol 2012, 59:1413-1425.
    • (2012) J Am Coll Cardiol , vol.59 , pp. 1413-1425
    • De Caterina, E.1    Husted, S.2    Wallentin, L.3
  • 48
    • 14144250885 scopus 로고    scopus 로고
    • Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism
    • Veeger N.J., Piersma-Wichers M., Tijssen J.G., et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005, 128:513-519.
    • (2005) Br J Haematol , vol.128 , pp. 513-519
    • Veeger, N.J.1    Piersma-Wichers, M.2    Tijssen, J.G.3
  • 49
    • 33646468354 scopus 로고    scopus 로고
    • Effect of study setting on anticoagulation control: a systematic review and metaregression
    • van Walraven C., Jennings A., Oake N., et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006, 129:1155-1166.
    • (2006) Chest , vol.129 , pp. 1155-1166
    • van Walraven, C.1    Jennings, A.2    Oake, N.3
  • 50
    • 57149140461 scopus 로고    scopus 로고
    • Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range
    • Connolly S.J., Pogue J., Eikelboom J., et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008, 118:2029-2037.
    • (2008) Circulation , vol.118 , pp. 2029-2037
    • Connolly, S.J.1    Pogue, J.2    Eikelboom, J.3
  • 51
    • 84856632988 scopus 로고    scopus 로고
    • Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls
    • 379-338
    • Samama M.M., Contant G., Spiro T.E., et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012, 107. 379-338.
    • (2012) Thromb Haemost , vol.107
    • Samama, M.M.1    Contant, G.2    Spiro, T.E.3
  • 52
    • 84856293397 scopus 로고    scopus 로고
    • Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial
    • Samama M.M., Contant G., Spiro T.E. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 2012, 18:150-158.
    • (2012) Clin Appl Thromb Hemost , vol.18 , pp. 150-158
    • Samama, M.M.1    Contant, G.2    Spiro, T.E.3
  • 53
    • 78649736882 scopus 로고    scopus 로고
    • Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay
    • Barrett Y.C., Wang Z., Frost C., et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010, 104:1263-1271.
    • (2010) Thromb Haemost , vol.104 , pp. 1263-1271
    • Barrett, Y.C.1    Wang, Z.2    Frost, C.3
  • 54
    • 84855886240 scopus 로고    scopus 로고
    • Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US 50. payer's perspective
    • Duran A., Sengupta N., Diamantopoulos A., et al. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US 50. payer's perspective. Pharmacoeconomics 2012, 30:87-101.
    • (2012) Pharmacoeconomics , vol.30 , pp. 87-101
    • Duran, A.1    Sengupta, N.2    Diamantopoulos, A.3
  • 55
    • 81255214516 scopus 로고    scopus 로고
    • Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective
    • Duran A., Sengupta N., Diamantopoulos A., et al. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective. J Med Economics 2011, 14:824-834.
    • (2011) J Med Economics , vol.14 , pp. 824-834
    • Duran, A.1    Sengupta, N.2    Diamantopoulos, A.3
  • 56
    • 79959263039 scopus 로고    scopus 로고
    • Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban
    • Friedman R.J., Sengupta N., Lees M. Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban. Expert Rev Pharmacoeconomics Outcomes Res 2011, 11:299-306.
    • (2011) Expert Rev Pharmacoeconomics Outcomes Res , vol.11 , pp. 299-306
    • Friedman, R.J.1    Sengupta, N.2    Lees, M.3
  • 57
    • 77958133516 scopus 로고    scopus 로고
    • Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada
    • Diamantopoulos A., Lees M., Wells P.S., et al. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thrombosis Haemostasis 2010, 104:760-770.
    • (2010) Thrombosis Haemostasis , vol.104 , pp. 760-770
    • Diamantopoulos, A.1    Lees, M.2    Wells, P.S.3
  • 58
    • 84865456696 scopus 로고    scopus 로고
    • Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation
    • Lee S., Anglade M.W., Pham D., et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012, 110:845-851.
    • (2012) Am J Cardiol , vol.110 , pp. 845-851
    • Lee, S.1    Anglade, M.W.2    Pham, D.3
  • 59
    • 80054071757 scopus 로고    scopus 로고
    • Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
    • Fox K.A., Piccini J.P., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011, 32:2387-2394.
    • (2011) Eur Heart J , vol.32 , pp. 2387-2394
    • Fox, K.A.1    Piccini, J.P.2    Wojdyla, D.3
  • 60
    • 84856802635 scopus 로고    scopus 로고
    • Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    • Kearon C., Akyl E.A., Comerata A.J., et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(Suppl):e419S-e494S.
    • (2012) Chest , vol.141 , Issue.SUPPL
    • Kearon, C.1    Akyl, E.A.2    Comerata, A.J.3
  • 61
    • 84869131278 scopus 로고    scopus 로고
    • Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome
    • Komosci A., Vorobcsuk A., Kehl D., et al. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome. Arch Intern Med 2012, 172:1537-1545.
    • (2012) Arch Intern Med , vol.172 , pp. 1537-1545
    • Komosci, A.1    Vorobcsuk, A.2    Kehl, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.